TCG Crossover

TCG Crossover, which goes by TCGX, describes itself as an investment firm focused on innovative biotech companies. It says it backs entrepreneurs who use recent scientific breakthroughs to develop transformative medicines, and that it supports both private and public companies. The About page lists offices in Palo Alto, San Francisco and New York City and says the firm has supported companies in North America, Europe and China. A press release from October 2026 adds new offices in Shanghai and Hong Kong.^[1],[2]

TCGX calls its money patient capital. It invests out of closed-end funds, which it says means it faces no redemption pressure and does not have to sell one position to fund another. The firm says that structure lets it provide capital at any stage of a company's lifecycle, which is the crossover idea in its name: its news page carries both private financings and public offerings. TCGX also describes a Science Network of leading scientists, including Nobel Prize and Lasker Award recipients, and says it uses its own resources to help portfolio companies diligence new pipeline opportunities, navigate the capital markets and execute geographic expansions.^[1],[3]

The SEC filing we opened is for TCG Crossover Fund I, L.P., a Delaware limited partnership that gives 2021 as its year of organization and 15 January 2021 as its date of first sale. It is an amendment, filed in 2021. It reports a total offering amount of $800,000,000, an equal amount sold, and 79 investors. The related person is Chen Yu, described as managing member of the general partner, and the issuer address is in Palo Alto, California.^[4]

On 7 October 2026 TCGX announced the closing of the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million vehicle backed by international institutional investors. The release says it will invest in biotechnology companies based in Asia, will operate separately from but in close synergy with the Flagship Funds, which focus on the United States and Europe, and keeps dedicated investment teams and regional focus. The release is a paid press release distributed through Business Wire.^[2]

Chen Yu is the founder and managing partner. The team page says he spent sixteen years as a managing partner at Vivo Capital before founding TCGX, and earlier held leadership roles at private and public companies, including COO of Sagent Pharmaceuticals and chief business officer of China KangHui, both of which went public and were later acquired. It says he has led investments in, or served on the boards of, over a dozen private and public companies, and that he holds an M.D. and an M.B.A. from Stanford and a B.A. in biology from Harvard.^[5]

The investment team also includes senior associates George Feng, Haithem Laaribi and Suan Tuang, associate Michael Albert, and analysts Bill Zhang and Ali Niazi. Craig Skaling is COO and CFO, Casey Cwynar is general counsel and chief compliance officer, Brad Balter is head of trading, and Ed Amorosi is head of capital formation and investor relations. The page also lists science partners: Robert Tjian, Roger Perlmutter, Charles Sawyers, Richard Scheller, Vishva Dixit, Huda Zoghbi, Charles Zuker and Helen Hobbs.^[5]

The team page names several companies as acquired. Chester's bio lists RAPT (acquired by GSK), Vicebio (Sanofi), Icosavax (AstraZeneca), Iveric (Astellas), Gracell (AstraZeneca), Versanis (Eli Lilly), Akouos (Eli Lilly), VectivBio (Ironwood), Carmot (Roche) and Tourmaline (Novartis) as past TCGX investments. Marostica's bio says he has led investments in Chinook (Novartis), Cymabay (Gilead) and Inhibrx (Sanofi), and in CG Oncology, which went public in January 2024; it does not say which of his employers made them. The news page headline for Vicebio reads "to be acquired by Sanofi for US$1.6 billion." The bios give no TCGX ownership share or proceeds for any of them.^[5],[3]

The news page also carries 2026 acquisition announcements for Forte Biosciences (argenx, July), Candid Therapeutics (UCB, May) and Centessa Pharmaceuticals (Lilly, March). None of these companies appears in the bios we read, so we treat them as portfolio news and not as confirmed TCGX exits. These announcements describe agreements to acquire; we did not check whether any deal has closed.^[3],[5]